BRPI0809124A8 - COMPOSITIONS AND METHODS FOR TREATMENT OF PEDIATRIC HYPOGONADISM - Google Patents

COMPOSITIONS AND METHODS FOR TREATMENT OF PEDIATRIC HYPOGONADISM

Info

Publication number
BRPI0809124A8
BRPI0809124A8 BRPI0809124A BRPI0809124A BRPI0809124A8 BR PI0809124 A8 BRPI0809124 A8 BR PI0809124A8 BR PI0809124 A BRPI0809124 A BR PI0809124A BR PI0809124 A BRPI0809124 A BR PI0809124A BR PI0809124 A8 BRPI0809124 A8 BR PI0809124A8
Authority
BR
Brazil
Prior art keywords
treatment
methods
compositions
testosterone
hypogonadism
Prior art date
Application number
BRPI0809124A
Other languages
Portuguese (pt)
Inventor
E Dudley Robert
D Rogol Alan
Benesh Janet
L Zumbrunnen Troy
Pratt Gregg
J Brennan John
Lagast Hjalmar
Original Assignee
Unimed Pharmaceuticals Llc
Laboratoires Besins Int
Besins Healthcare Luxembourg S A R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unimed Pharmaceuticals Llc, Laboratoires Besins Int, Besins Healthcare Luxembourg S A R L filed Critical Unimed Pharmaceuticals Llc
Publication of BRPI0809124A2 publication Critical patent/BRPI0809124A2/en
Publication of BRPI0809124A8 publication Critical patent/BRPI0809124A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

USO DE TESTOSTERONA, PACOTE FARMACÊUTICO E RECIPIENTE DE MÚLTIPLAS DOSES PARA O TRATAMENTO DE HIPOGONADISMO PEDIÁTRICO. A presente invenção refere-se a composições destinadas ao tratamento de indivíduos pré-pubertais do sexo masculino na fase da adolescência com insuficiente produção de testosterona, usando uma formulação de gel de testosterona hidroalcoólico que fornece, entre outras coisas, um desejável perfil hormonal farmacocinético, e métodos para tratamento dos ditos adolescentes do sexo masculino.USE OF TESTOSTERONE, PHARMACEUTICAL PACK AND MULTI-DOSE CONTAINER FOR THE TREATMENT OF PEDIATRIC HYPOGONADISM. The present invention relates to compositions intended for the treatment of prepubertal adolescent males with insufficient testosterone production, using a hydroalcoholic testosterone gel formulation that provides, among other things, a desirable hormonal pharmacokinetic profile, and methods for treating so-called male adolescents.

BRPI0809124A 2007-03-23 2008-03-20 COMPOSITIONS AND METHODS FOR TREATMENT OF PEDIATRIC HYPOGONADISM BRPI0809124A8 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07104726 2007-03-23
EP07104726.0 2007-03-23
PCT/EP2008/053372 WO2008116825A2 (en) 2007-03-23 2008-03-20 Compositions and method for treating pediatric hypogonadism

Publications (2)

Publication Number Publication Date
BRPI0809124A2 BRPI0809124A2 (en) 2014-08-26
BRPI0809124A8 true BRPI0809124A8 (en) 2015-11-24

Family

ID=38321980

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0809124A BRPI0809124A8 (en) 2007-03-23 2008-03-20 COMPOSITIONS AND METHODS FOR TREATMENT OF PEDIATRIC HYPOGONADISM

Country Status (10)

Country Link
EP (1) EP2136813A2 (en)
JP (1) JP2010521519A (en)
CN (1) CN101754764A (en)
AU (1) AU2008231781B2 (en)
BR (1) BRPI0809124A8 (en)
CA (1) CA2623477C (en)
EA (1) EA018775B1 (en)
IL (1) IL200887A0 (en)
MX (1) MX2009008995A (en)
WO (1) WO2008116825A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3755B1 (en) * 2011-01-26 2021-01-31 Ferring Bv Testosterone formulations
DK2714006T3 (en) * 2011-05-15 2021-03-15 Acerus Biopharma Inc Intranasal bioadhesive testosterone gel formulations and their use in the treatment of male hypogonadism

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20030139384A1 (en) * 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
US20040072810A1 (en) * 2001-11-07 2004-04-15 Besins International Belgique Pharmaceutical composition in the form of a gel or a solution based on dihydrotestosterone, process for preparing it and uses thereof
US7138389B2 (en) * 2004-02-09 2006-11-21 University Of Washington Oral androgen therapy using modulators of testosterone bioavailability
CN101287470B (en) * 2005-10-12 2012-10-17 优尼麦德药物股份有限公司 Improved testosterone gel and method of use

Also Published As

Publication number Publication date
AU2008231781A1 (en) 2008-10-02
EA018775B1 (en) 2013-10-30
EA200901288A1 (en) 2010-04-30
CN101754764A (en) 2010-06-23
CA2623477C (en) 2011-05-31
WO2008116825A3 (en) 2008-11-27
CA2623477A1 (en) 2008-09-23
WO2008116825A2 (en) 2008-10-02
EP2136813A2 (en) 2009-12-30
MX2009008995A (en) 2009-09-03
BRPI0809124A2 (en) 2014-08-26
JP2010521519A (en) 2010-06-24
IL200887A0 (en) 2010-05-17
AU2008231781B2 (en) 2012-09-20

Similar Documents

Publication Publication Date Title
BR112012010706A2 (en) compound, pharmaceutical composition, pharmaceutical combination, use of a compound, and methods for treating a disease or condition, and for inhibiting bromodomain
BR112014008731A2 (en) multiple sclerosis treatment with combination of laquinimode and fingolimode
BR112015011403A2 (en) use of akkermansia for the treatment of metabolic disorders
BRPI0916668A2 (en) c5 complement protein targeting antibody compositions and methods
BRPI0919753B8 (en) polymorphic form of palmitoylethanolamide, pharmaceutical composition for human or veterinary use, method for micronization of palmitoylethanolamide and ultramicronized palmitoylethanolamide
BR112014011841A2 (en) hydrophobic drug delivery material, method for producing the same and methods for delivering a drug delivery composition
BR112014031394A2 (en) compositions and methods for transmucosal absorption
BRPI0617294B8 (en) pharmaceutical composition in hydroalcoholic gel and use of testosterone
BR112014000380A2 (en) pharmaceutical composition, methods of treatment and uses thereof
BR112012005044B8 (en) pharmaceutical composition comprising a combination of (rac)-tramadol·hcl and celecoxib
BR112015009037A2 (en) pharmaceutical composition for use in the treatment of myocardial infarction and use of a hmgb1 fragment peptide
BR112015006093A2 (en) combination of rasagiline and pridopidine for the treatment of neurodegenerative disorders, particularly in huntington's disease
BRPI0806863B8 (en) use of a phorbol ester in the preparation of a drug to prevent or treat an HIV infection
BR112014018953A8 (en) TRITERPENOID LUPANE DERIVATIVES AND PHARMACEUTICAL USE THEREOF
CO6710913A2 (en) Use of lysosomal lipase acid to treat lysosomal lipase acid deficiency in patients
BR112012012862A2 (en) pharmaceutical composition comprising oligopeptides
BR112015008297A2 (en) mglu2 / 3 antagonists for the treatment of autistic disorders
BR112013001301A2 (en) a process for preparing a liquid pharmaceutical composition comprising human immunoglobulin g and a liquid pharmaceutical composition containing human immunoglobulin g
BRPI1013288A2 (en) use of a compound, pharmaceutical composition method for the treatment of diseases in which abnormal gastrointestinal motility is involved, kit and commercial package comprising a pharmaceutical composition containing the compound
BRPI0916069C1 (en) compound, uses of a compound, pharmaceutical composition, cosmetic composition and cosmetic uses of a composition
BR112015000321A2 (en) Laquinimod formulations without alkalizing agent
BR112012015202A2 (en) "Iota - and / or kappa-carrageenate together with a neuraminidase inhibitor, method for the prophylactic or therapeutic treatment of a symptom, condition or disease, pharmaceutical composition, and kit of parts."
BRPI0911469A8 (en) GM-CSF AND IL-17 INHIBITORS FOR THERAPY
BR112014027047A2 (en) new formulation
BR112013004562A2 (en) Substituted 2-oxyquinoline-3-carboxamides as modulators kcnq2 / 3

Legal Events

Date Code Title Description
B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: A PETICAO DE NO 20130017075, APRESENTADA EM 28/02/2013, EM VIRTUDE DO DISPOSTO NOS ARTS. 218 OU 219 DA LPI (LEI 9279 / 96) DE 14/05/1996, E CONSIDERADA COMO PETICAO NAO CONHECIDA POR AUSENCIA DE FUNDAMENTACAO LEGAL, POIS O NOME EMPRESARIAL E O ENDERECO DO TITULAR SAO OS MESMOS PARA OS QUAIS SE PEDEM AS ALTERACOES.

B25A Requested transfer of rights approved

Owner name: UNIMED PHARMACEUTICALS LLC (US) , BESINS HEALTHCAR

B25G Requested change of headquarter approved

Owner name: UNIMED PHARMACEUTICALS LLC (US) , BESINS HEALTHCARE LUXEMBOURG S.A.R.L. (LU)

Owner name: UNIMED PHARMACEUTICALS LLC (US) , BESINS HEALTHCAR

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL